Association of concomitant proton pump inhibitor use with worse survival outcomes in patients with advanced gastric cancer receiving ramucirumab
British Journal of Clinical Pharmacology · 2025
DOI: 10.1002/bcp.70202 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Takuya Kaneko und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University of Tsukuba Hospital, Ibaraki, Japan. Hauptthemen laut MEDLINE: Stomach Neoplasms, Proton Pump Inhibitors, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Aims
Vascular endothelial growth factor (VEGF)‐A binding to VEGF receptor (VEGFR)2 promotes tumour angiogenesis and progression. Proton pump inhibitors (PPIs) upregulate VEGF‐A expression in various cancers. This study examined the association between concomitant PPI use and survival outcomes in patients with advanced gastric cancer (AGC) receiving ramucirumab, a VEGFR2‐targeting monoclonal antibody, plus paclitaxel (PTX) or nab‐paclitaxel (nab‐PTX). The impact of PPI use on serum VEGF‐A concentrations was also evaluated.
Methods
This retrospective study included 152 patients with AGC receiving ramucirumab plus PTX/nab‐PTX as a second‐line therapy. Progression‐free survival (PFS) was compared between PPI and non‐PPI users. Multivariate Cox proportional hazards analysis was used to assess the prognostic factors for PFS. Serum VEGF‐A concentrations were measured in blood samples from 25 patients at baseline and on Day 14 following the first ramucirumab infusion.
Results
Median PFS was 3.7 months (95% confidence interval [CI]: 2.8–4.7) for PPI users and 4.7 months (95% CI: 4.0–5.3) for non‐PPI users (hazard ratio [HR]: 1.44; 95% CI: 1.01–2.06; P = 0.040). Multivariate analysis, adjusted for age, the Glasgow prognostic score, total gastrectomy and massive ascites, identified PPI use as a prognostic factor for PFS (HR: 1.48; 95% CI: 1.02–2.14; P = 0.038). Serum VEGF‐A concentrations were higher in PPI users than in non‐PPI users at baseline and during ramucirumab therapy.
Conclusions
Concomitant PPI use was associated with shorter PFS in patients with AGC receiving ramucirumab plus PTX/nab‐PTX, likely due to elevated serum VEGF‐A concentrations during treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, University of Tsukuba Hospital, Ibaraki, Japan.
- Department of Pharmaceutical Sciences, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan.
- Division of Gastroenterology, University of Tsukuba Hospital, Ibaraki, Japan.
ORCID-Profile: Kosuke Doki
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Kaneko, T., Doki, K., Yamada, T., Uda, M., Yamamoto, Y., Kobayashi, M., Tsuchiya, K., & Homma, M. (2025). Association of concomitant proton pump inhibitor use with worse survival outcomes in patients with advanced gastric cancer receiving ramucirumab. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70202
Vancouver
Kaneko T, Doki K, Yamada T, Uda M, Yamamoto Y, Kobayashi M, et al. Association of concomitant proton pump inhibitor use with worse survival outcomes in patients with advanced gastric cancer receiving ramucirumab. British Journal of Clinical Pharmacology. 2025. doi:10.1002/bcp.70202
BibTeX
@article{Kaneko2025,
author = {Kaneko, Takuya and Doki, Kosuke and Yamada, Takeshi and Uda, Masato and Yamamoto, Yoshiyuki and Kobayashi, Mariko and Tsuchiya, Kiichiro and Homma, Masato},
title = {Association of concomitant proton pump inhibitor use with worse survival outcomes in patients with advanced gastric cancer receiving ramucirumab},
journal = {British Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1002/bcp.70202}
}
EUVIMED